Search

everythinglearnresearchcommunity

for

Search:↓

MK-386 and finasteride together effectively reduce DHT levels, potentially treating acne and male pattern baldness.

Finasteride almost fully depletes allopregnanolone in rat brains and enhances 20α-DHP, but doesn't change 3α-DHP levels.

Drugs that block DHT production can effectively treat enlarged prostate and improve urinary issues with some sexual side effects.

5α-reductase inhibitors may prevent prostate cancer but could also raise the risk of more severe cancers.

Finasteride treats enlarged prostate and hair loss, but may cause side effects in some patients.

Testosterone's muscle-building effects do not require its conversion to DHT.

Men over 66 taking medication for prostate enlargement have a higher risk of depression and self-harm, especially in the first 18 months of treatment.

5α-reductase inhibitors increase the risk of sexual dysfunction, especially in men with enlarged prostate.

Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.

Too much AKR1C3 enzyme causes resistance to finasteride by increasing testosterone.

5-alpha reductase deficiency leads to male sexual development issues and treatments like finasteride help with prostate enlargement and hair loss.

5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.

Curcuma aeruginosa extract combined with minoxidil effectively treats male-pattern baldness.

Using finasteride or dutasteride does not increase the risk of male breast cancer.

Taking 5α-reductase inhibitors does not significantly increase the risk of breast cancer in men.

Benzo[c]quinolizin-3-ones are effective nonsteroidal inhibitors of human steroid 5α-reductase 1.

New compounds may soon be tested to treat excessive hair growth in women.

Men taking 5-alpha-reductase inhibitors before or after bladder cancer diagnosis had a lower risk of dying from the disease.